Stocks to watch today include Kotak Mahindra Bank, Axis Bank, Marico, Trent, Zydus Lifesciences, Vedanta, Laser Power & Infra and Narayana Hrudayalaya after fresh Q2 business updates, a ₹1,012 crore acquisition, a first-generic US drug launch and new corporate actions.
Indian equities enter Tuesday with a stronger global backdrop and several company-specific triggers after the Nifty 50 rose 0.60% to 22,555.75 on Monday.
The rebound came after Indian benchmarks suffered their longest weekly losing streak in 25 years, but the next major macro test is already close: the Reserve Bank of India’s monetary policy decision is due on October 7.
Against that backdrop, Tuesday’s stock-specific news is unusually strong.
Kotak Mahindra Bank has reported 24.7% growth in net advances, Axis Bank’s advances increased 22.7%, Trent’s Q2 revenue jumped 23%, Marico has invested another ₹1,012.03 crore in the parent of PLIX, and Zydus Lifesciences has launched the first generic version of Adempas in the US.
But some of today’s biggest numbers need a second look.
For banks, the impact of FCNR(B) deposits means headline growth does not tell the entire funding story. For Trent, rapid expansion still needs to translate into store productivity and margins. And for Marico, investors will eventually judge the PLIX transaction by the earnings generated from the capital deployed.
Track Live: GIFT NIFTY, NIFTY 50, SENSEX, FII DII DATA
Stocks to Watch Today: Key Triggers at a Glance
| Stock | Fresh Trigger | Key Thing to Watch |
|---|---|---|
| Kotak Mahindra Bank | Net advances +24.7%, deposits +23.2% | CASA growth and FCNR(B) impact |
| Axis Bank | Advances +22.7%, deposits +20.7% | 18.8% underlying advance growth after specified adjustment |
| Marico | ₹1,012.03 crore PLIX-parent stake purchase | Return from higher ownership |
| Trent | Q2 revenue +23% to ₹5,788 crore | Store productivity and margins |
| Zydus Lifesciences | First generic Adempas launch in US | Uptake, pricing and competition |
| Vedanta | Board meets October 8 on interim dividend | Dividend amount, if declared |
| Laser Power & Infra | ₹72.76 crore POWERGRID order | Execution of growing order book |
| Narayana Hrudayalaya | 110-bed Bengaluru hospital operational | Ramp-up of new capacity |
1. Kotak Mahindra Bank: 24.7% Loan Growth, But Funding Quality Is the Bigger Story
Kotak Mahindra Bank reported net advances of ₹5,77,094 crore as of September 30, 2026, up 24.7% from a year earlier.
Total deposits increased 23.2% YoY to ₹6,51,491 crore.
On the surface, both numbers point to strong balance-sheet expansion.
The more interesting detail is the funding mix.
CASA balances increased only 11.3% YoY to ₹2,49,105 crore, significantly slower than overall deposit growth.
Kotak also disclosed around $5.78 billion of FCNR(B) deposits raised under the RBI swap facility and around $1.68 billion of advances extended against those deposits through international branches.
Why Kotak is important today
The 24.7% advance-growth headline is clearly strong, but investors may look beyond it to answer three questions:
- How sustainable is the pace of loan growth?
- Can CASA growth catch up with total deposit growth?
- What does the changing funding mix mean for margins and funding costs?
The Q2 business-update numbers are provisional, so the full quarterly results will provide a clearer picture of profitability and margins.
2. Axis Bank: 22.7% Headline Growth Drops to 18.8% After FCNR-Linked Adjustment
Axis Bank reported gross advances of ₹13.846 lakh crore, up 22.7% YoY and 8.8% sequentially.
Total deposits increased 20.7% YoY to ₹14.521 lakh crore, while CASA deposits grew at a slower 10.6%.
Axis also mobilised approximately $10.62 billion of FCNR(B) deposits under the RBI facility.
Importantly, the bank itself disclosed the impact of those flows.
Excluding specified loans linked to the FCNR(B) deposits, gross advances would have grown 18.8% YoY instead of 22.7%.
Deposit growth on the corresponding adjusted basis would have been around 17% YoY, against the reported 20.7%.
What the market may focus on
This does not make Axis’s growth weak.
Instead, it shows why investors should distinguish between reported balance-sheet growth and underlying operating growth.
CASA trends, funding costs and eventual net-interest-margin performance may matter more than the headline percentage alone.
A broader banking signal
IndusInd Bank adds another layer to Tuesday’s banking story.
Its net advances increased 11.2% YoY, but the CASA ratio fell to 28%, from 30.7% a year earlier.
Across several banks, the common theme is therefore not simply credit growth. It is credit growth versus funding quality.
3. Marico: ₹1,012 Crore PLIX Deal Gets More Interesting When You Look at Growth
Marico has acquired an additional 24.09% stake in Satiya Nutraceuticals for ₹1,012.03 crore, raising its ownership from 60% to 84.09%.
Satiya Nutraceuticals owns the digital-first health and wellness brand PLIX.
The transaction is one of the strongest stock-specific triggers in today’s market because it combines a large capital commitment with a fast-growing underlying business.
Satiya’s consolidated turnover increased to ₹864.31 crore in FY26 from ₹432.84 crore in FY25, nearly doubling in a year.
That growth helps explain why Marico is increasing its exposure to the wellness business.
Marico has separately indicated double-digit consolidated revenue growth for Q2.
What investors should watch
The question is no longer whether PLIX is growing.
The bigger question is whether Marico can turn that growth into sufficient earnings, cash flow and return on the additional capital deployed.
Higher ownership gives Marico more economic exposure to the business, but the long-term value of the deal will depend on profitability and execution.
4. Trent: 23% Revenue Growth Is Strong — Now Store Productivity Matters
Trent reported standalone Q2 FY27 revenue of ₹5,788 crore, up 23% from ₹4,724 crore a year earlier.
First-half revenue increased 21% to ₹11,454 crore.
The company’s retail network reached 1,342 stores by September-end, while Zudio has crossed the 1,000-store milestone.
During Q2, Trent added a net 17 Zudio stores and 10 Westside stores.
These are strong expansion numbers.
But the latest update does not provide detailed EBITDA, profit or margin figures.
Why that matters
Store count can drive topline growth, but increasingly the market will want to know:
How productive are those stores?
As Trent’s network gets larger, same-store performance, margins and returns from new locations become more important than the store-count milestone alone.
That makes the upcoming profitability numbers an important second test for the retailer.
5. Zydus Lifesciences: First Generic Adempas Launch Creates a US Opportunity
Zydus Lifesciences, in partnership with MSN Laboratories, has launched the first generic version of Adempas (riociguat tablets) in the US.
The product is being launched across all five strengths:
0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg.
A first-generic launch can provide a meaningful commercial opportunity, particularly before competitive intensity increases.
But being first does not automatically establish the eventual earnings contribution.
What matters next
For Zydus, investors may monitor:
- Market uptake
- Pricing
- Competitive generic launches
- Market share
- Sales contribution
- Margin contribution
The launch is a clear catalyst. Its financial value will become clearer as commercial performance develops.
6. Vedanta: Interim Dividend Decision Due October 8
Vedanta’s board will meet on October 8, 2026 to consider and approve the first interim dividend for FY27, if any.
The company has fixed October 14 as the record date for determining eligible shareholders if the dividend is declared.
No dividend amount has been announced ahead of the meeting.
Why Vedanta is on the watchlist
The stock now has a clearly defined near-term corporate-action trigger.
However, investors should avoid assuming a particular payout based on previous dividends. The actual market response will depend on the amount declared, if any, along with commodity prices and the broader market environment.
7. Laser Power & Infra: Recent Orders Reach ₹116.76 Crore
Laser Power & Infra has secured a ₹72.76 crore POWERGRID order covering HTLS conductor supply and reconductoring work for two 132 kV transmission lines.
The project covers around 164 circuit-km and has an execution period of approximately 12 months.
The company also recently received a ₹44 crore CESC EPC order/letter of intent.
Together, the two recent awards represent ₹116.76 crore of order value.
Order value is only the first step
Fresh orders improve revenue visibility, but contract wins do not automatically translate into equivalent profits.
The next factors to monitor are:
- Execution speed
- Working-capital requirements
- Revenue recognition
- Project margins
- Completion timelines
For an order-driven business, execution becomes more important once the announcement is made.
8. Narayana Hrudayalaya: Bengaluru Hospital Goes Live, Kolkata Adds Asset-Light Expansion
Narayana Hrudayalaya commenced commercial operations at its 110-bed KS-Narayana Hospital in Banashankari, Bengaluru, on October 5.
The company has also signed a long-term operation-and-management agreement for the 100-bed Mission of Mercy Hospital & Research Centre in Kolkata.
Commercial operations at the Kolkata facility could take up to 12 months to begin.
The Kolkata agreement is particularly notable because it follows an asset-light O&M model, rather than requiring Narayana to own the underlying hospital property.
What investors may monitor
Hospital expansion can support longer-term growth, but new capacity rarely reaches mature occupancy immediately.
Ramp-up speed, occupancy, operating execution and eventual economics will determine how quickly these additions contribute meaningfully to earnings.
Also on the Radar
Godrej Consumer Products: The company expects high-teens consolidated Q2 revenue growth, high-single-digit underlying volume growth and double-digit EBITDA growth. Input inflation in crude derivatives and palm oil remains an important margin variable.
AWL Agri Business: Q2 revenue increased 24% while volumes grew 12%. Its Food & FMCG business crossed ₹2,000 crore in quarterly revenue for the first time, with segment revenue rising 33%.
Hi-Tech Pipes: Q2 FY27 sales volumes reached a record 165,016 MT, up 32% YoY. The next question is whether higher volumes translate proportionately into earnings.
Metropolis Healthcare: Q2 revenue grew around 15%, supported by double-digit volume growth, while EBITDA margins improved year-on-year and sequentially.
What Could Drive Stocks Today?
Banks: Headline Growth vs Underlying Quality
This is the most important analytical theme in Tuesday’s company updates.
Kotak and Axis both reported headline balance-sheet growth above 20%, but their FCNR(B) disclosures mean investors have more to analyse than the topline percentage.
The key questions are now around:
CASA growth, cost of deposits, underlying credit growth and margin sustainability.
That is likely to become increasingly important when the banks publish complete Q2 financial results.
Consumer Stocks: Growth Still Has to Prove Profitability
Trent and Marico have two of today’s most compelling corporate stories.
Trent is expanding rapidly and has delivered 23% revenue growth, but profitability and store productivity remain important.
Marico is deploying another ₹1,012.03 crore into a business whose turnover nearly doubled last year. The growth is visible; return on capital now becomes the key test.
Pharma: A First-Mover Opportunity Is Not the Same as Guaranteed Earnings
Zydus’s first generic Adempas launch is commercially significant.
But pricing, market penetration and competing launches will ultimately determine how valuable that first-mover position becomes.
Order-Book Stocks: Execution Becomes the Next Catalyst
Laser Power’s fresh orders improve visibility.
Once the contract is won, however, investor attention should shift from order size to execution, margins and cash conversion.
RBI Policy Adds a Macro Test on October 7
Company-specific triggers could dominate individual stocks on Tuesday, but index direction still faces a major macro event.
The RBI is due to announce its monetary policy decision on Wednesday, October 7.
The rupee, crude oil prices, interest-rate expectations and foreign institutional flows could therefore remain important for broader market sentiment.
Foreign investors were net sellers on Monday, while domestic institutions continued to provide support.
That means strong corporate news does not necessarily guarantee a positive stock reaction if the broader risk environment changes.
Key Takeaways
Today’s watchlist is strongest when the headline number is paired with the question behind it.
Kotak Mahindra Bank: 24.7% advance growth, but CASA and funding mix deserve attention.
Axis Bank: 22.7% reported advance growth versus 18.8% after the bank’s specified FCNR-linked adjustment.
Marico: ₹1,012.03 crore for additional PLIX-parent ownership, backed by a business whose turnover nearly doubled in FY26.
Trent: 23% Q2 revenue growth and more than 1,000 Zudio stores, with margins and store productivity still to be seen.
Zydus Lifesciences: First generic Adempas in the US creates an opportunity, but commercial uptake will decide its value.
Vedanta: October 8 dividend decision creates a clearly defined near-term trigger.
Laser Power & Infra: ₹116.76 crore across two recent awards, with execution now becoming the important variable.
Narayana Hrudayalaya: New hospital capacity expands the network, but occupancy ramp-up will determine earnings contribution.
Bottom Line
Stocks to watch today are being driven by unusually strong company-specific news, but the most important opportunities lie in understanding what sits behind the headline numbers.
Kotak and Axis have reported strong balance-sheet growth, yet funding composition adds an important second layer to the story.
Marico is increasing its exposure to a rapidly growing wellness business through a ₹1,012.03 crore transaction.
Trent’s 23% revenue growth confirms strong expansion momentum, though store productivity and margins will ultimately matter more than store count.
Zydus has secured a potentially valuable first-generic US opportunity, while Vedanta has a defined dividend catalyst ahead.
For Laser Power and Narayana Hrudayalaya, the next stage is execution: converting fresh orders and new capacity into sustainable earnings.
And above all of these stock-specific stories sits Wednesday’s RBI policy decision, which could quickly influence risk appetite across the broader market.
Read Next: RBL Bank Q2 Loan Growth Hits 40%: PNB, BoB, AU SFB Show Why Deposits Matter
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, research advice or a recommendation to buy, sell or hold any security. Investments in securities markets are subject to market risks. Business updates and provisional figures may be subject to statutory review, subsequent exchange disclosures or revision.
